The MCRS1 antibody targets the microspherule protein 1 (MCRS1), a multifunctional protein implicated in diverse cellular processes, including cell cycle regulation, RNA processing, and chromatin remodeling. MCRS1 interacts with key partners such as the Aurora A kinase (AURKA) and the tumor suppressor INI1/hSNF5. influencing mitotic progression, centrosome duplication, and genomic stability. Structurally, MCRS1 contains coiled-coil and SEF (similar to elongation factor) domains, enabling interactions with multiple molecular complexes.
MCRS1 is overexpressed in cancers like hepatocellular carcinoma and glioblastoma, correlating with poor prognosis due to its roles in promoting proliferation, metastasis, and apoptosis resistance. Antibodies against MCRS1 are widely used in techniques like Western blotting, immunofluorescence, and ChIP to study its localization, expression dynamics, and interactions. These antibodies typically recognize epitopes within conserved regions, such as the N-terminal domain, and help identify post-translational modifications like phosphorylation that regulate MCRS1 activity.
Commercial MCRS1 antibodies (e.g., from Sigma-Aldrich, Abcam) are often raised in rabbits or mice using recombinant protein fragments or synthetic peptides. Validation includes detecting the ~75 kDa endogenous protein in cell lysates and confirming specificity via knockdown controls. Research utilizing these antibodies has advanced understanding of MCRS1's oncogenic mechanisms and its potential as a therapeutic target.